List of Prialt drug patents
Prialt is owned by Tersera.
Prialt contains Ziconotide Acetate.
Prialt has a total of 3 drug patents out of which 0 drug patents have expired.
Prialt was authorised for market use on 28 December, 2004.
Prialt is available in injectable;intrathecal dosage forms.
Prialt can be used as treatment of pain; analgesia, treatment of severe chronic pain via intrathecal infusion of ziconotide in patients also receiving morphine, analgesia; treatment of pain.
The generics of Prialt are possible to be released after 01 October, 2024.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8653033 | TERSERA | Method for administering omega-conopeptide |
Oct, 2024
(1 year, 5 months from now) | |
| US8765680 | TERSERA | Method for administering omega-conopeptide |
Oct, 2024
(1 year, 5 months from now) | |
| US9707270 | TERSERA | Method for administering ω-conopeptide |
Oct, 2024
(1 year, 5 months from now) | |
Drugs and Companies using ZICONOTIDE ACETATE ingredient
Market Authorisation Date: 28 December, 2004
Treatment: Analgesia; Treatment of pain; Treatment of severe chronic pain via intrathecal infusion of ziconotide in patients also receiving morphine
Dosage: INJECTABLE;INTRATHECAL
PRIALT family patents
17
United States
2
Canada
2
Japan
1
European Union
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic